Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -8.06
- Piotroski Score 3.00
- Grade Buy
- Symbol (ME)
- Company 23andMe Holding Co.
- Price $0.33
- Changes Percentage (-1.52%)
- Change -$0.01
- Day Low $0.33
- Day High $0.37
- Year High $1.09
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/07/2024
- Fiscal Year End N/A
- Average Stock Price Target $3.71
- High Stock Price Target $7.00
- Low Stock Price Target $0.42
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.40
- Trailing P/E Ratio -0.29
- Forward P/E Ratio -0.29
- P/E Growth -0.29
- Net Income $-666,704,000
Income Statement
Quarterly
Annual
Latest News of ME
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
UK leader Starmer is facing flak for taking freebies. He says he's done nothing wrong
British Prime Minister Keir Starmer faces criticism over donations from a wealthy businessman and high salary of his top aide. Starmer denies impropriety and claims the attacks are politically motivat...
By AP NEWS | 13 hours ago -
Starmer's free tickets for Arsenal and Taylor Swift part of job, says minister
Business secretary Jonathan Reynolds defended Labour leader Keir Starmer's acceptance of gifts, stating it is part of the job to attend major cultural and sporting events. Reynolds emphasized the need...
By The Guardian | 13 hours ago -
Target names Jim Lee as CFO
Target has appointed Jim Lee as its new chief financial officer, starting on September 22. Lee brings over 25 years of financial and business expertise from PepsiCo. He will manage financial planning,...
By Yahoo! Finance | 13 hours ago